Novartis AG
METHOD OF TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17)
Last updated:
Abstract:
The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
Status:
Application
Type:
Utility
Filling date:
1 Nov 2018
Issue date:
17 Jun 2021